COVID-19 testing will keep boosting revenues even as the pandemic wanes, says pathology, radiology and laboratory group Sonic Healthcare, estimating it will level out at between 10 per cent and 20 per cent of peak testing levels in coming years.
Chief executive Colin Goldschmidt did not provide earnings guidance for the $15.9 billion ASX-listed company because of the unpredictability of the pandemic, which boosted testing revenues for the group in the past year.
Loading...
Jemima Whyte writes on business, specialising in companies, capital markets and innovation. Jemima has reported on business for The Australian Financial Review for more than 13 years. Email Jemima at jemima.whyte@afr.com
